Key Takeaway: Precision BioSciences has reported its fourth quarter and fiscal year 2023 financial results. The company has initiated final studies for its lead in vivo gene editing program, PBGENE-HBV, and anticipates submitting an IND and/or CTA in 2024. Additionally, Precision has completed licensing agreements to monetize its divested CAR T assets, generating nearly $50 million in upfront payments.
Price reaction · baseline $12.75 (2024-03-26 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+1.8%
Market Sentiment Analysis
POSITIVE FACTORS
Initiated final studies for PBGENE-HBV program.
Expecting to submit IND/CTA in 2024.
Completed licensing agreements to monetize CAR T assets.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Initiated final IND/CTA enabling studies for lead in vivo gene editing program PBGENE-HBV; expect to submit IND and/or CTA in 2024 – Completed licensing agreements to monetize divested CAR T assets with Imugene , TG Therapeutics and Caribou Biosciences including nearly $50 million in upfront and
Frequently Asked Questions
What is PBGENE-HBV?
PBGENE-HBV is Precision BioSciences' lead in vivo gene editing program.
When does Precision expect to submit the IND/CTA?
Precision expects to submit the IND and/or CTA in 2024.
What financial agreements did Precision complete?
Precision completed licensing agreements to monetize its divested CAR T assets.
How much did the licensing agreements generate?
The licensing agreements generated nearly $50 million in upfront payments.